New IPF drug trial halted: what happened?

NCT ID NCT06317285

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tested a new medicine called GSK3915393 for people with idiopathic pulmonary fibrosis (IPF), a chronic lung disease that causes scarring and breathing difficulty. The trial aimed to see if the drug could slow lung function decline, but it was terminated early. About 158 participants were planned, and the main measure was change in forced vital capacity (a lung function test) after 26 weeks.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • GSK Investigational Site

    Newport Beach, California, 92663, United States

  • GSK Investigational Site

    Jacksonville, Florida, 32224, United States

  • GSK Investigational Site

    St. Petersburg, Florida, 33704, United States

  • GSK Investigational Site

    Ann Arbor, Michigan, 48109-5360, United States

  • GSK Investigational Site

    Rochester, Minnesota, 55905, United States

  • GSK Investigational Site

    New York, New York, 10065, United States

  • GSK Investigational Site

    Wilmington, North Carolina, 28401, United States

  • GSK Investigational Site

    Philadelphia, Pennsylvania, 19140, United States

  • GSK Investigational Site

    Nashville, Tennessee, 37204, United States

  • GSK Investigational Site

    Cypress, Texas, 77429, United States

  • GSK Investigational Site

    Buenos Aires, C1426ABP, Argentina

  • GSK Investigational Site

    Ciudad Autonoma de Bueno, C1207AAP, Argentina

  • GSK Investigational Site

    Florida, B1602DQD, Argentina

  • GSK Investigational Site

    La Plata, 1900, Argentina

  • GSK Investigational Site

    Mendoza, M5500CCG, Argentina

  • GSK Investigational Site

    Rosario, S2000DBS, Argentina

  • GSK Investigational Site

    Vancouver, British Columbia, V5Z 1M9, Canada

  • GSK Investigational Site

    St. John's, Newfoundland and Labrador, A1B 3V6, Canada

  • GSK Investigational Site

    Ajax, Ontario, L1S 2J5, Canada

  • GSK Investigational Site

    Hamilton, Ontario, L8N 4A6, Canada

  • GSK Investigational Site

    Trois-Rivières, Quebec, G8T 7A1, Canada

  • GSK Investigational Site

    La Tronche, 38700, France

  • GSK Investigational Site

    Paris, 75018, France

  • GSK Investigational Site

    Pessac, 33604, France

  • GSK Investigational Site

    Rennes, 35000, France

  • GSK Investigational Site

    Rouen, 76000, France

  • GSK Investigational Site

    Toulouse, 31059, France

  • GSK Investigational Site

    Essen, 45293, Germany

  • GSK Investigational Site

    Hanover, 30173, Germany

  • GSK Investigational Site

    Heidelberg, 69126, Germany

  • GSK Investigational Site

    Wuppertal, 42283, Germany

  • GSK Investigational Site

    Catania, 95123, Italy

  • GSK Investigational Site

    Monza MB, 20900, Italy

  • GSK Investigational Site

    Naples, Italy

  • GSK Investigational Site

    Padova, 35128, Italy

  • GSK Investigational Site

    Perugia, 06132, Italy

  • GSK Investigational Site

    Pisa, 56124, Italy

  • GSK Investigational Site

    Roma, 00168, Italy

  • GSK Investigational Site

    Sassari, 07100, Italy

  • GSK Investigational Site

    Torrette AN, Italy

  • GSK Investigational Site

    Eindhoven, 5623 EJ, Netherlands

  • GSK Investigational Site

    Rotterdam, 3015 CE, Netherlands

  • GSK Investigational Site

    Bialystok, 15-044, Poland

  • GSK Investigational Site

    Lodz, 90-153, Poland

  • GSK Investigational Site

    Poznan, 60-569, Poland

  • GSK Investigational Site

    Barcelona, 08907, Spain

  • GSK Investigational Site

    Barcelona, Spain

  • GSK Investigational Site

    Madrid, 28006, Spain

  • GSK Investigational Site

    Madrid, 28007, Spain

  • GSK Investigational Site

    Oviedo, 33011, Spain

  • GSK Investigational Site

    Pozuelo de AlarcOn Madr, 28223, Spain

  • GSK Investigational Site

    Santander, 39011, Spain

  • GSK Investigational Site

    Seville, 41013, Spain

  • GSK Investigational Site

    Edinburgh, EH16 4SA, United Kingdom

  • GSK Investigational Site

    Leeds West Yorkshire, LS9 7TF, United Kingdom

  • GSK Investigational Site

    London, SW3 6HP, United Kingdom

Conditions

Explore the condition pages connected to this study.